Abstract

Objective: Using a large U.S. claims database (MarketScan), we investigated the controversy surrounding the role of statins in Parkinson's disease (PD). Methods: We performed a retrospective case-control analysis. First, we identified 2322 incident PD cases having a minimum of 2.5 years of continuous enrollment prior to earliest diagnosis code or prescription of antiparkinson medication. A total of 2322 controls were then matched individually by age, gender, and a follow-up window to explore the relationship of statin use with incident PD. Results: Statin usage was significantly associated with PD risk, with the strongest associations being for lipophilic (odds ratio = 1.58, P <.0001) versus hydrophilic (odds ratio = 1.19, P =.25) statins, statins plus nonstatins (odds ratio = 1.95, P <.0001), and for the initial period after starting statins (<1 year odds ratio = 1.82, 1-2.5 years odds ratio = 1.75, and ≥2.5 years odds ratio = 1.37; Ptrend <.0001). Conclusion: The use of statin (especially lipophilics) was associated with higher risk of PD, and the stronger association in initial use suggests a facilitating effect.

Original languageEnglish (US)
Pages (from-to)913-917
Number of pages5
JournalMovement Disorders
Volume32
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Parkinson Disease
Databases
Odds Ratio
Prescriptions
Early Diagnosis

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

@article{b0a04df517274c57a4f81088817b61c7,
title = "Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database",
abstract = "Objective: Using a large U.S. claims database (MarketScan), we investigated the controversy surrounding the role of statins in Parkinson's disease (PD). Methods: We performed a retrospective case-control analysis. First, we identified 2322 incident PD cases having a minimum of 2.5 years of continuous enrollment prior to earliest diagnosis code or prescription of antiparkinson medication. A total of 2322 controls were then matched individually by age, gender, and a follow-up window to explore the relationship of statin use with incident PD. Results: Statin usage was significantly associated with PD risk, with the strongest associations being for lipophilic (odds ratio = 1.58, P <.0001) versus hydrophilic (odds ratio = 1.19, P =.25) statins, statins plus nonstatins (odds ratio = 1.95, P <.0001), and for the initial period after starting statins (<1 year odds ratio = 1.82, 1-2.5 years odds ratio = 1.75, and ≥2.5 years odds ratio = 1.37; Ptrend <.0001). Conclusion: The use of statin (especially lipophilics) was associated with higher risk of PD, and the stronger association in initial use suggests a facilitating effect.",
author = "Guodong Liu and Sterling, {Nicholas W.} and Lan Kong and Mechelle Lewis and Richard Mailman and Honglei Chen and Douglas Leslie and Xuemei Huang",
year = "2017",
month = "6",
day = "1",
doi = "10.1002/mds.27006",
language = "English (US)",
volume = "32",
pages = "913--917",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

Statins may facilitate Parkinson's disease : Insight gained from a large, national claims database. / Liu, Guodong; Sterling, Nicholas W.; Kong, Lan; Lewis, Mechelle; Mailman, Richard; Chen, Honglei; Leslie, Douglas; Huang, Xuemei.

In: Movement Disorders, Vol. 32, No. 6, 01.06.2017, p. 913-917.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Statins may facilitate Parkinson's disease

T2 - Insight gained from a large, national claims database

AU - Liu, Guodong

AU - Sterling, Nicholas W.

AU - Kong, Lan

AU - Lewis, Mechelle

AU - Mailman, Richard

AU - Chen, Honglei

AU - Leslie, Douglas

AU - Huang, Xuemei

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Objective: Using a large U.S. claims database (MarketScan), we investigated the controversy surrounding the role of statins in Parkinson's disease (PD). Methods: We performed a retrospective case-control analysis. First, we identified 2322 incident PD cases having a minimum of 2.5 years of continuous enrollment prior to earliest diagnosis code or prescription of antiparkinson medication. A total of 2322 controls were then matched individually by age, gender, and a follow-up window to explore the relationship of statin use with incident PD. Results: Statin usage was significantly associated with PD risk, with the strongest associations being for lipophilic (odds ratio = 1.58, P <.0001) versus hydrophilic (odds ratio = 1.19, P =.25) statins, statins plus nonstatins (odds ratio = 1.95, P <.0001), and for the initial period after starting statins (<1 year odds ratio = 1.82, 1-2.5 years odds ratio = 1.75, and ≥2.5 years odds ratio = 1.37; Ptrend <.0001). Conclusion: The use of statin (especially lipophilics) was associated with higher risk of PD, and the stronger association in initial use suggests a facilitating effect.

AB - Objective: Using a large U.S. claims database (MarketScan), we investigated the controversy surrounding the role of statins in Parkinson's disease (PD). Methods: We performed a retrospective case-control analysis. First, we identified 2322 incident PD cases having a minimum of 2.5 years of continuous enrollment prior to earliest diagnosis code or prescription of antiparkinson medication. A total of 2322 controls were then matched individually by age, gender, and a follow-up window to explore the relationship of statin use with incident PD. Results: Statin usage was significantly associated with PD risk, with the strongest associations being for lipophilic (odds ratio = 1.58, P <.0001) versus hydrophilic (odds ratio = 1.19, P =.25) statins, statins plus nonstatins (odds ratio = 1.95, P <.0001), and for the initial period after starting statins (<1 year odds ratio = 1.82, 1-2.5 years odds ratio = 1.75, and ≥2.5 years odds ratio = 1.37; Ptrend <.0001). Conclusion: The use of statin (especially lipophilics) was associated with higher risk of PD, and the stronger association in initial use suggests a facilitating effect.

UR - http://www.scopus.com/inward/record.url?scp=85017440764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017440764&partnerID=8YFLogxK

U2 - 10.1002/mds.27006

DO - 10.1002/mds.27006

M3 - Article

C2 - 28370314

AN - SCOPUS:85017440764

VL - 32

SP - 913

EP - 917

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 6

ER -